Kenneth L. Waggoner, J.D. – Chief Executive Officer, President, General Counsel and Chairman of the Board


Kenneth L. Waggoner serves as the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech and is the Chairman of the Board. He has 50 years of experience in management, business, operations and law. Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients, including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. He was the Managing Partner of Brobeck’s Los Angeles office. Mr. Waggoner was also a member of Brobeck’s Executive Committee for almost ten years and on Brobeck’s Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues more than $750,000,000. While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner’s career includes leadership and legal positions at Chevron as Vice President and General Counsel of Chevron’s global downstream business after Chevron’s acquisition of Texaco. While at Chevron he was responsible for the overall management of legal services to the North American, Latin American, European and Asian products companies of Chevron, including refining, distribution, shipping and technology, and served on Chevron’s Global Downstream Executive Committee. During his tenure at Chevron, Mr. Waggoner led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco and Gulf Oil.

Further highlights of Mr. Waggoner’s career included management and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.

Mr. Waggoner received his Juris Doctorate with honors in 1973 from Loyola University School of Law in Los Angeles.

Dr. Gerald W. Crabtree – Chief Operating Officer and Director


Dr. Gerald W. Crabtree is the Chief Operating Officer of PharmaCyte Biotech and a Board member. He has spent almost 50 years working in academic, biotech and pharmaceutical companies with the majority of that vast experience being in the development of drugs and treatments for cancer. He has held positions of ever-increasing importance over that time. Dr. Crabtree’s background in the biomedical sciences has been substantial, having been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, and research and review articles.

A highlight of Dr. Crabtree’s professional career was his tenure as Director of Project Planning and Management (Oncology and Immunology) at Bristol-Myers Squibb (“BMS”) from 1990 to 1997. While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval within BMS and served as Project Manager for the development of the major anticancer agent, Taxol®, the “number one” drug under development at BMS at that time. Taxol® ultimately became a multi-billion dollar drug for BMS and is still widely used to treat a variety of cancers.

From 1989 to 1990, Dr. Crabtree was Director of Pharmacology at Viratek, Inc., a subsidiary of ICN Pharmaceuticals, Inc. in Costa Mesa, California. There he worked on the development of anticancer drugs first developed at the Nucleic Acid Research Institute (NARI, a joint venture between Eastman Kodak and ICN Pharmaceuticals) and with ribavirin (Virazole®), Viratek’s landmark antiviral drug. From 1985 to 1989, Dr. Crabtree served as Head of the Department of Molecular Pharmacology at NARI where his department was tasked with elucidating the mechanisms of action of anticancer and antiviral drugs developed by NARI chemists. From 1970 to 1985, Dr. Crabtree held several faculty positions at Brown University in Providence Rhode Island as well as at the Roger Williams Cancer Center (“RWCC”) at that institution. These positions culminated in his attaining the rank of Associate Professor of Medicine. During his time at Brown and the RWCC, Dr. Crabtree studied the mechanisms of action of putative anticancer and antiparasitic drugs and participated in clinical trials of anticancer agents.

After leaving BMS in 1997, Dr. Crabtree consulted with several biotech companies, all of which were developing cancer drugs or treatments. Then, from 2000 to 2003, Dr. Crabtree served as Vice President of R&D at ETEX Corporation, a “device” company, where he was tasked with developing that company’s proprietary calcium phosphate formulations as depot/delivery platforms for cancer drugs. Upon leaving ETEX, he resumed his consulting business, which soon became focused on PhytoCeutica, Inc. located in the Yale Science Park in New Haven, Connecticut, where he assisted in the preparation and review of FDA documents, clinical study protocols, investment acquisitions, and contracts and business plans. PhytoCeutica was developing a traditional Chinese medicine four-herb combination as a treatment for liver and pancreatic cancer. During his time with PhytoCeutica, Dr. Crabtree assumed ever-increasing responsibilities and from 2009 to 2010, ultimately serving as its Interim CEO. Dr. Crabtree resumed his consulting business after leaving PhytoCeutica until he joined PharmaCyte Biotech.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada, and has published over 80 articles in peer-reviewed journals. He was a National Cancer Institute of Canada Research Fellow. Dr. Crabtree is currently a member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on research grant review committees for the National Institutes of Health and the American Cancer Society.

Dr. Linda S. Sher – Chief Medical Officer

Dr. Linda S. Sher

Dr. Sher is a Professor of Clinical Surgery in the Division of Hepatobiliary/Pancreatic Surgery and Abdominal Organ Transplantation in the Department of Surgery at the University of Southern California’s Keck School of Medicine (USC). Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery at USC where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board.

Dr. Sher oversees the structure, conduct and reporting of PharmaCyte’s clinical trials and represents PharmaCyte in its interactions with the company’s clinical trial investigators, regulatory agencies, key opinion leaders, the investment, medical and regulatory communities, as well as pharmaceutical and biotechnology sector collaborators and potential partners.

After completing her medical school education and surgical residency at Mount Sinai School of Medicine in New York, Dr. Sher had fellowship training at the University of Pittsburgh in Liver and Kidney Transplantation under the tutelage of Dr. Thomas Starzl. Dr. Starzl was a renowned physician, researcher and expert on organ transplants. He performed the first liver transplant and is often referred to as “the father of modern transplantation.” Following completion of her fellowship program in 1988, Dr. Sher was involved in the establishment of two liver transplant programs in Los Angeles before joining the USC program in 2001.

Dr. Sher has participated in the surgery and management of more than 700 patients. She has been the Principal or Co-Principal Investigator for more than 50 clinical trials and has mentored young faculty at USC in the conduct of clinical trials. Dr. Sher is active in the clinical and basic science research components of the Abdominal Organ Transplantation Program at USC. She has authored or co-authored publications on immunosuppression, chronic rejection, disease recurrence, infection, and prophylaxis and hepatobiliary surgery. Dr. Sher is one of the original editors of Current Opinion in Organ Transplantation, which provides the reader with an up to date overview of the entire field of organ transplantation.

Prof. Dr. Walter H. Günzburg – Chief Scientific Officer


Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association’s Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as Nature, The Lancet, Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Carlos A. Trujillo, CPA – Chief Financial Officer and Director

Carlos A. Trujillo

Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech and is a member of PharmaCyte’s Board of Directors. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has 35 years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors.

For the last eleven years, Mr. Trujillo has been the Chief Financial Officer for both privately-held and publicly-traded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports.

Mr. Trujillo received his Bachelor’s Degree in Accounting in 1982 from California State University, Fullerton.

Dr Matthias Löhr – Medical and Scientific Advisory Board Chairman

dr. matthias lohr

Dr. Matthias Löhr is the Chairman of the PharmaCyte Biotech Scientific Advisory Board. Dr. Löhr served as Principal Investigator for the Phase 1/2 and Phase 2 clinical trials of PharmaCyte Biotech’s pancreatic cancer treatment that were completed in the early 2000s. Not only is he familiar with the Cell-in-a-Box® live cell encapsulation technology that forms the core of PharmaCyte Biotech’s pancreatic cancer treatment, he has actually administered PharmaCyte Biotech’s treatment (the combination of Cell-in-a-Box® capsules with low doses of the well-known anticancer drug ifosfamide) in clinical trials in patients with advanced, inoperable pancreatic cancer. Dr. Löhr is also serving as a consultant to PharmaCyte Biotech in connection with its development of treatments for pancreatic cancer and diabetes based on the Cell-in-a-Box® technology. Dr. Löhr has expertise in the treatment of both diseases in addition to thoroughly understanding the Cell-in-a-Box® technology and its use in a clinical setting.

Dr. Löhr is Professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden. He has also served as Professor of Molecular Gastroenterology at the University of Heidelberg and Head of a division at the German Cancer Research Center. Dr. Löhr has also worked as a translational scientist and Principal Investigator in clinical studies in gastrointestinal oncology for many years and has completed a postdoctoral fellowship at the Scripps Clinic & Research Foundation in La Jolla, California. Following receipt of his medical degree, Dr. Löhr served a residency in pathology and a residency in internal medicine and gastroenterology in Erlangen and Rostock in Germany, where he was also an Assistant Professor. Dr. Löhr holds a Ph.D. and an M.D. from the Karolinska University Hospital, Stockholm, Sweden. In addition, Dr. Löhr is a Member of Clinical Cooperation Unit of Molecular Gastroenterology at the German Cancer Research Centre, Heidelberg, Germany.

Dr. Eva-Maria Brandtner – Diabetes Program Director


Dr. Eva-Maria Brandtner is PharmaCyte’s Diabetes Program Director. Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy. In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company. Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation. This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology. Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes. Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation. She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings. Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).

Dr. Mark L. Rabe – Cannabis Program Director

Mark L. Rabe, M.D. – Director of Cannabis Program Development

Dr. Mark L. Rabe is PharmaCyte’s Cannabis Program Director. He has over three decades of experience providing medical care to tens of thousands of patients as a highly regarded clinical physician. His integrative holistic medical practice, Centric Wellness, is located in San Diego, California. He is also CEO of Rabe Medical Solutions, LLC, a consulting, education and software company.

Dr. Rabe has worked with PharmaCyte since 2013, when he was appointed as founding member and Chairman of the Medical and Scientific Advisory Board. In this role, he was instrumental in building the Board, designing PharmaCyte’s cannabinoid-based therapy and establishing PharmaCyte’s current Cannabis research program with the University of Northern Colorado. As Cannabis Program Director, Dr. Rabe leads strategic planning, management and development of PharmaCyte’s Cell-in-a-Box® cannabinoid-based therapy. The Program is currently in the preclinical research phase. He also provides operational support to the Chief Executive Officer and executive management team.

In addition to his clinical practice, Dr. Rabe has held a variety of senior management positions in the health care industry. He owned and operated regional businesses that provided mobile health services to insurance companies. He was Medical Director of an e-Learning company that provided computer-based educational programs, including advanced training in oncology, to physicians and scientists at companies such as Eli Lilly, Celgene, Genentech, Amgen and others. He was Medical Director of a health services company with a workforce of several thousand independent examiners, in all 50 states, providing mobile screening and wellness services to a variety of corporate customers. Dr. Rabe has also served as Chief Medical Officer of a network of twenty physician-owned integrative health clinics across the state of California specializing in the recommendation of natural treatment options. Dr. Rabe serves as a California Superior Court-approved expert witness in the emerging area of cannabinoid medicine.

Dr. Rabe attended the Feinberg School of Medicine at Northwestern University. He is a diplomate of the American Board of Integrative Holistic Medicine (ABIHM). He received his undergraduate training at Benedictine University, where he earned a summa cum laude degree in biochemistry and performed research in cancer drug synthesis.

Dr. Rabe has provided numerous scientific and educational presentations in the field of how Cannabis can be used to treat various diseases, including cancer.